Ra Medical Systems has secured the US Food and Drug Administration (FDA) clearance to begin investigational device exemption (IDE) to study its DABRA excimer laser system as an atherectomy device to treat peripheral vascular stenoses.

DABRA system eliminates blockages from arteries in the limbs and is efficient on all types of lesions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition to altering the arteries, DABRA can bypass the lesion and cross the chronic total occlusions (CTOs) with a wire.

During the trial, 100 patients will be registered with symptoms of peripheral vascular disease (PAD) (Rutherford Class 2-4).

The principal efficacy endpoint of the study is the mean decrease in diameter stenosis in patients’ primary lesion following DABRA treatment before adjunctive treatment.

The safety and clinical success endpoints for the study is characterised by main adverse events during 30 days and the occurrence of primary target lesion revascularisation at six months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ra Medical Systems CFO and interim CEO Andrew Jackson said: “We are delighted the FDA has granted this IDE allowing us to pursue an atherectomy indication for DABRA and anticipate enrolling the first patient into the trial in the next few months.

“We believe DABRA produces minimal vascular trauma due to its unique use of photochemical ablation that dissolves plaque into its molecular components, which may make DABRA a preferred treatment.

“Atherectomy with mechanical devices can cause trauma to vessel walls, often resulting in restenosis or a return of the blockage months following the procedure.”

In May 2017, Ra Medical Systems had secured approval from the US FDA to market its laser radiation ablation (DABRA) system to treat peripheral artery disease (PAD).